In 2024 , LordsMed envisions pioneering technological breakthroughs
efficiency . Our commitment to innovation was further exemplified by our strategic alignment with the National Medical Devices Policy , playing a vital role in fostering the growth of the medical device sector . This initiative not only ensured access , affordability , and quality but also stimulated domestic investments and production .
Our subsidiaries , including LordsMed , Lord ’ s Mark Microbiotech , and Lord ’ s Mark Biotech , played instrumental roles in driving the development of groundbreaking medtech products and expanding the production of innovative diagnostic solutions . Noteworthy milestones include the successful pan- India expansion of our pathology lab and the initiation of global exports for our medical diagnostic products , marking a significant stride in establishing a substantial international footprint . The introduction of a salivabased technology for genome testing under our subsidiary ' s MyDNA brand stands as a major accomplishment , symbolizing a significant leap in personalized medicine . These achievements reflect our unwavering dedication to research , innovation , and strategic alliances . As we navigate the ever-evolving healthcare landscape , we anticipate continued growth and impactful contributions in the years ahead .
In 2024 , LordsMed envisions pioneering technological breakthroughs
Turning to diagnostics in 2024 , the industry witnesses pivotal trends . Artificial intelligence , advanced algorithms , and point-of-care testing enhance accuracy , expedite processes , and offer profound insights . This reflects a silent revolution , emphasizing our commitment to delivering swift , precise diagnostic results .
Innovations like liquid biopsy technology quietly advance , promising non-invasive improvements in disease detection and enhanced patient experiences . Collaborations between diagnostics and digital health platforms promote seamless communication and increased accessibility . The rise of genetic medical applications signals a shift towards individualized diagnoses . In 2024 , the diagnostics industry is set to usher in an era of enhanced precision and personalized care through its discreet evolution .
In 2024 , LordsMed envisions pioneering technological breakthroughs to transform the healthcare industry . We are committed to expanding our footprint in medtech product development and diagnostic solutions , ensuring cutting-edge healthcare offerings . Over the next 3-5 years , our goal is to reach Tier 2 and Tier 3 towns , connecting with 1 lac doctors directly or digitally . Our ultimate aspiration is to provide preventive genetic tests to the majority of Indians , alleviating the burden of chronic illnesses .
BIOVOICENEWS . COM 27